Payson LeMeilleur is a partner in our Orange County office. Mr. LeMeilleur has litigated patent infringement cases in United States District Courts nationwide, as well as at the Federal Circuit and International Trade Commission. Mr. LeMeilleur has represented both plaintiffs and defendants in many technological areas, including pharmaceuticals and mechanical, biomedical and electronic devices.
Mr. LeMeilleur joined the firm in 1999 and became a partner in 2005.
Education
University of Virginia School of Law
(J.D., 1999)
University of Southern California (USC)
(B.S. Physics, 1996), Phi Beta Kappa Honor Society, Phi Kappa Phi Honor Society, magna cum laude
Pfizer Inc. et al. v. Ranbaxy Labs. Ltd. et al., 1:08-cv-00164 (2008).
Represented defendants in patent infringement action in the District of Delaware on two patents relating to methods of making atorvastatin (the active ingredient in Pfizer’s Lipitor® product). Achieved favorable case-dispositive settlement for client.
Pfizer Inc. et al. v. Ranbaxy Labs. Ltd. et al., 1:08-cv-00162 (2008).
Represented defendants in patent infringement action in the District of Delaware on two patents relating to methods of making atorvastatin (one of the active ingredients in Pfizer’s Caduet® product). Achieved favorable case-dispositive settlement for client.
Pfizer Inc. et al. v. Ranbaxy Labs. Ltd. et al., 1:07-cv-00138 (2007).
Represented defendants in patent infringement action on method patent relating to the use of atorvastatin calcium/amlodipine besylate (the active ingredients in Pfizer’s Caduet® product). Achieved favorable case-dispositive settlement for client.
Pfizer Inc. v. Ranbaxy Labs. Ltd., 457 F.3d 1284 (Fed. Cir. 2006).
Represented defendants in patent infringement action in the District of Delaware on two patents relating to atorvastatin calcium (the active ingredient in Pfizer’s Lipitor® product). On appeal following a two-week bench trial, the Court of Appeals for the Federal Circuit invalidated the later-expiring patent.
Astellas Pharma Inc. et al. v. Ranbaxy Labs. Ltd. et al., 3:05-cv-02563 (2005).
In patent infringement action in the District of New Jersey on patent relating to tamsulosin (the active ingredient in Astellas’ Flomax® product), assisted in briefing before the district court and the Court of Appeals for the Federal Circuit. The case settled prior to a decision by the Court of Appeals for the Federal Circuit.
AstraZeneca AB et al. v. Ranbaxy Labs. Ltd. et al., 3:05-cv-05553 (2005).
Represented defendants in patent infringement action in the District of New Jersey concerning six patents related to esomeprazole magnesium (the active ingredient in AstraZeneca’s Nexium® product). Achieved favorable settlement for client.
Ranbaxy Labs. Ltd. et al. v. Abbott Labs. et al., 1:04-cv-8078 (2004).
Represented declaratory judgment plaintiff in the Northern District of Illinois on three patents relating to extended-release formulations of clarithromycin (the active ingredient in Abbott’s Biaxin XL® product). At preliminary injunction stage, achieved ruling that two patents were likely invalid for inequitable conduct. Subsequently achieved favorable case-dispositive settlement for client.
Custom TeleConnect, Inc. v. International Tele-Services, Inc., 254 F. Supp.2d 1173 (D. Nev. 2003).
Successfully defeated summary judgment motions on behalf of the plaintiff in a breach of contract and tortious interference case. Obtained monetary settlement for plaintiff through subsequent litigation.
Glaxo Group Ltd. v. Ranbaxy Pharms. Inc., 262 F.3d 1333 (Fed. Cir. 2001).
Represented defendants through six-week bench trial in the District of New Jersey on patent relating to cefuroxime axetil (the active ingredient in Glaxo’s Ceftin® product). Achieved judgment of noninfringement of patent. Plaintiff did not appeal district court decision.
In the Matter of Certain Personal Watercraft and Components Thereof, USITC Inv. No. 337-TA-452 (2001).
Represented Complainant patentee in investigation of accused products pursuant to Section 337 of the Tariff Act of 1930, as amended. Case settled after four-week hearing before administrative law judge.